Verastem Inc
VSTM
查看详细走势图
6.670USD
+0.390+6.21%
收盘 02/06, 16:00（美东）报价延迟15分钟
445.22M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+6.21%
5天
+9.34%
1月
-12.70%
6月
+18.68%
今年开始到现在
-13.60%
1年
+15.20%
查看详细走势图
TradingKey Verastem Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Verastem Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名99/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价16.62。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Verastem Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Verastem Inc亮点
亮点风险
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
业绩高增长
公司营业收入稳步增长，连续3年增长285.21%
业绩增长期
公司处于发展阶段，最新年度总收入10.00M美元
利润高增长
公司净利润处于行业前列，最新年度总收入10.00M美元
估值合理
公司最新PE估值-1.56，处于3年历史合理位
机构减仓
最新机构持股68.58M股，环比减少4.44%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值125.61K
活跃度增加
近期活跃度增加，过去20天平均换手率1.20
分析师目标
根据
9
位分析师
买入
评级
16.625
目标均价
+144.85%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Verastem Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Verastem Inc简介
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
公司代码VSTM
公司Verastem Inc
CEOPaterson (Daniel W)
网址https://www.verastem.com/
相关品种
